

Protecting Livestock

IMPROVING HUMAN LIVES



Protecting Livestock – Improving Human Lives





Across the world, livestock are vital to **communities and economies**

The livelihoods and subsistence of 1.3 billion people worldwide are dependent on the livestock sector - for food and nutrition security, income and employment, and economic growth. The sector contributes 40 per cent of the agricultural output in developing countries and is a major contributor to meeting the **2030 Agenda for Sustainable Development**.

Livestock diseases, however, pose a significant risk, complicated further by the fact that **effective vaccines and affordable medicines** are not widely available and accessible to **small-scale producers (SSPs)** in developing countries.

To support the transformation needed, GALVmed seeks to unlock the development potential of sustainable livestock production through improved **animal health products** and functional, self-sustaining markets. GALVmed's vision of success is a world where markets supplying small-scale producers function well.

1.3 billion
people worldwide

are dependent on the
livestock sector.



And contributes

40%

of the agricultural output
in developing countries.



SOLUTION

To bring the changes that will enable small-scale producers to better feed the world while bettering themselves, GALVmed's pathway to sustainable impact is focused on:



Improved, more accessible animal health products for SSPs.



Reduced burden of SSPs livestock disease.



Reduced mortality/morbidity AND increased use of improved inputs and husbandry practices.



Significantly improved livestock productivity. Better efficiency, less waste.



Improved lives and livelihoods for SSPs. Stronger rural economies.



Some income re-invested in animal health inputs...viable business for commercial partners.

Vision

Transformational improvement in the wellbeing and economic progression of small-scale livestock producers.

Mission

To contribute to the transformation of small-scale livestock producers' lives by:

- Understanding constraints to animal health and how to overcome them.
- Engaging the animal health industry.
- Ensuring awareness, availability and adoption of effective animal health interventions at SSP-level.

What **WE DO**



IMPROVE AVAILABILITY: Facilitating partnerships with universities, research institutes, and the private sector to develop high impact health interventions.



INCREASE ACCESSIBILITY: Working with private sector partners who are willing to develop sustainable and scalable business models that focus on serving small-scale producer segments.



IMPROVE ADOPTION: Working with advocacy groups, regulators, the animal health industry and government bodies to ease barriers in the regulatory and market environment.



INCREASE UNDERSTANDING: Delivering pragmatic data and information from the SSP field which quantifies impact and informs strategy and operational plans.



How we are **MAKING A DIFFERENCE:**



Creating **prosperous and sustainable markets** across Africa and South Asia.



Working with national regulators to establish **clear, coherent animal health policies.**



De-risking private sector investments by conducting **unprofitable but valuable research** and development.



Promoting cooperation between the public and private sectors.



Boosting incomes, **improving lives** and strengthening national economies.

PRIORITY DISEASES: We determine the diseases to prioritise based on the size and location of the problem, whether alternative solutions already exist, and if there are new technological solutions to bring to bear. In addition to our priority diseases, we will continue to consider the inclusion of additional diseases based on evidence of need and the potential for benefiting small-scale producers.



OUR IMPACT since 2014



1.2 billion livestock vaccines, therapeutics and other animal health products to SSP customers in 15 countries across Africa and South Asia.



Approximately **5.7 million** cumulative annual customers.



23.7 million livestock deaths averted saving the sector approximately \$386 million.



Approximately **\$119 million** of cattle mortalities averted from East Coast Fever disease (since 2010).



Approximately **\$52.5 million** in poultry deaths averted from Newcastle disease.



15 products developed.



A total of **9 products** to date have been registered under the East African Community Mutual Recognition Procedure (MRP).




Over 90 publications disseminated.

Where **WE WORK**

**OUR FOCUS IS ON AFRICA
AND SOUTH ASIA WHERE NEED
AND OPPORTUNITY ARE GREATEST**

(Kenya, Tanzania, Ethiopia, Nigeria and India).
We will however support commercial partners
taking a broader and more regional approach.



Path **AHEAD**

GALVmed will continue working with partners in the animal health industry, academia and research, policymakers, investors, and relevant organisations to help build on the progress to date and work together to protect livestock and improve human livelihoods.

GALVmed are best positioned to support the needs of the market with the business development requirements for the animal health industry. Strong partnerships with relevant actors and GALVmed will be necessary to expand livestock health products and build market momentum, in order to scale up effective and affordable vaccines and medicines for smallholders in the developing world.



CONTACT US

To learn more about GALVmed's work:



www.galvmed.org



@GALVmed



info@galvmed.org



@GALVmed



@galvmed



@Galvmed


GALVmed
Protecting Livestock – Improving Human Lives

With funding from

BILL & MELINDA
GATES *foundation*

